Caris Life Sciences (CAI) Cash from Operations Growth (1y) (2025 - 2026)
Powered by 
Analysis
Caris Life Sciences (CAI) Cash from Operations Growth (1y) (2025 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.74 Bn | 130.89 Bn | 2.84 Bn | 4.87% |
| 2 | Regeneron Pharmaceuticals | 85.52 Bn | 77.52 Bn | 3.93 Bn | -28.96% |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.04 Bn | 52.91 Bn | 52.00 Mn | 42.76% |
| 5 | Revolution Medicines | 44.06 Bn | 44.06 Bn | - | - |
| 6 | BeOne Medicines | 39.98 Bn | 34.88 Bn | 1.53 Bn | 75.58% |
| 7 | Alnylam Pharmaceuticals | 35.46 Bn | 32.15 Bn | 992.69 Mn | 151.70% |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | 100.14% |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | 56.79% |
| 10 | Caris Life Sciences | 7.02 Bn | 6.23 Bn | 182.38 Mn | 290.74% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 290.74% |
| Mar 31, 2026 | 204.91% |
| Dec 31, 2025 | 215.05% |
| Sep 30, 2025 | 189.91% |